InsiderClue

Insider trading

Period: 120 months Stock: TSHA Plan: Not on a plan × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

Create an account Sign in
When Periodin use
Who Role
The trade Type of trade Minimum amount Planin use Share of their own holding
Ownership What the chief executive holds
When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

1 month 12 months 120 months
53 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

Anyone CEO CFO Other officers Directors 10% owners
53 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

Any53 Buys21 Sells32 Cluster buys
53 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

Any $100K or more $1M or more $10M or more $100M or more $500M or more
53 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
Any Discretionary Scheduled (10b5-1) Not stated Not on a plan
53 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
53 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

53 decisions over 120 months
Stock
Insider
Type ?
Value ↓
Of own stake ↓
Why it stands out
TSHA Taysha Gene Therapies, Inc.
4 Feb 2026
Alam Kamran CHIEF FINANCIAL OFFICER
Sold at will
$7.48K 1,655 at 4.52
0.1%
Not planned
TSHA Taysha Gene Therapies, Inc.
26 Jan 2026
Nolan Sean P. Chief Executive Officer
Sold at will
$190.45K 41,312 at 4.61
1.4%
Not planned
TSHA Taysha Gene Therapies, Inc.
26 Jan 2026
Nagendran Sukumar President and Head of R&D
Sold at will
$124.09K 26,918 at 4.61
2.0%
Not planned
TSHA Taysha Gene Therapies, Inc.
26 Jan 2026
Alam Kamran CHIEF FINANCIAL OFFICER
Sold at will
$109.94K 23,849 at 4.61
1.6%
Not planned
TSHA Taysha Gene Therapies, Inc.
23 Jan 2026
Nolan Sean P. Chief Executive Officer
Sold at will
$649.75K 136,789 at 4.75
4.4%
Not planned
TSHA Taysha Gene Therapies, Inc.
23 Jan 2026
Nagendran Sukumar President and Head of R&D
Sold at will
$423.38K 89,132 at 4.75
6.2%
Not planned
TSHA Taysha Gene Therapies, Inc.
23 Jan 2026
Alam Kamran CHIEF FINANCIAL OFFICER
Sold at will
$375.10K 78,968 at 4.75
5.1%
Not planned
TSHA Taysha Gene Therapies, Inc.
1 Dec 2025
Nagendran Sukumar President and Head of R&D
Sold at will
$1.17M 260,047 at 4.51
20.5%
Not planned
TSHA Taysha Gene Therapies, Inc.
28 Nov 2025
Nagendran Sukumar President and Head of R&D
Sold at will
$523.09K 110,125 at 4.75
9.9%
Not planned
TSHA Taysha Gene Therapies, Inc.
21 Aug 2025
Nagendran Sukumar President and Head of R&D
Sold at will
$162.60K 57,054 at 2.85
4.7%
Not planned
TSHA Taysha Gene Therapies, Inc.
21 Aug 2025
Alam Kamran CHIEF FINANCIAL OFFICER
Sold at will
$155.30K 54,491 at 2.85
4.4%
Not planned
TSHA Taysha Gene Therapies, Inc.
30 May 2025
Manning Paul B 10% owner · indirect
Bought
$2.06M 750,000 at 2.75
35.9%
+36% of stake
TSHA Taysha Gene Therapies, Inc.
27 Jun 2024
Manning Paul B 10% owner
Bought
$3.00M 1,333,333 at 2.25
opened
TSHA Taysha Gene Therapies, Inc.
17 Nov 2023
Manning Paul B 10% owner · indirect
Bought
$163.00K 100,000 at 1.63
0.6%
TSHA Taysha Gene Therapies, Inc.
16 Aug 2023
Manning Paul B 10% owner · indirect
Bought
$14.82M 16,466,667 at 0.90
opened
Largest buy in 3 yrs
TSHA Taysha Gene Therapies, Inc.
16 Aug 2023
Nolan Sean P. Chief Executive Officer · indirect
Bought
$400.00K 444,444 at 0.90
40.7%
Largest buy in 3 yrs
TSHA Taysha Gene Therapies, Inc.
16 Aug 2023
Stalfort John A III Director
Bought
$350.00K 388,889 at 0.90
63.7%
First buy on file
TSHA Taysha Gene Therapies, Inc.
16 Aug 2023
Stalfort John A III Director · indirect
Bought
$350.00K 388,889 at 0.90
78.5%
First buy on file
TSHA Taysha Gene Therapies, Inc.
16 Aug 2023
Donenberg Phillip B. Director
Bought
$100.00K 111,111 at 0.90
×37
Largest buy in 3 yrs
TSHA Taysha Gene Therapies, Inc.
13 Jul 2023
Session R.A. II 10% owner
Sold at will
$3.74K 5,344 at 0.70
0.1%
Not planned
TSHA Taysha Gene Therapies, Inc.
12 Jul 2023
Session R.A. II 10% owner
Sold at will
$57.03K 80,528 at 0.71
0.9%
Not planned
TSHA Taysha Gene Therapies, Inc.
23 Jun 2023
Session R.A. II 10% owner
Sold at will
$12.74K 18,100 at 0.70
0.2%
Not planned
TSHA Taysha Gene Therapies, Inc.
22 Jun 2023
Session R.A. II 10% owner
Sold at will
$7.38K 10,508 at 0.70
0.1%
Not planned
TSHA Taysha Gene Therapies, Inc.
21 Jun 2023
Session R.A. II 10% owner
Sold at will
$97.63K 138,962 at 0.70
1.5%
Not planned
TSHA Taysha Gene Therapies, Inc.
20 Jun 2023
Session R.A. II 10% owner
Sold at will
$210.21K 295,653 at 0.71
3.1%
Not planned
TSHA Taysha Gene Therapies, Inc.
16 May 2023
Nagendran Sukumar President and Head of R&D
Bought
$3.40K 5,000 at 0.68
17.1%
TSHA Taysha Gene Therapies, Inc.
31 Oct 2022
Manning Paul B Director
Bought
$3.00M 1,500,000 at 2.00
×11
Largest buy in 3 yrs
TSHA Taysha Gene Therapies, Inc.
23 Aug 2022
Alam Kamran Chief Financial Officer
Sold, plan not stated
$11.54K 3,325 at 3.47
1.2%
TSHA Taysha Gene Therapies, Inc.
22 Aug 2022
Alam Kamran Chief Financial Officer
Sold, plan not stated
$34.01K 9,717 at 3.50
3.5%
TSHA Taysha Gene Therapies, Inc.
19 Aug 2022
Alam Kamran Chief Financial Officer
Sold, plan not stated
$43.06K 11,482 at 3.75
4.0%
TSHA Taysha Gene Therapies, Inc.
18 Aug 2022
Alam Kamran Chief Financial Officer
Sold, plan not stated
$28.93K 7,476 at 3.87
2.5%
TSHA Taysha Gene Therapies, Inc.
6 Jul 2022
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated
$33.94K 8,956 at 3.79
1.7%
TSHA Taysha Gene Therapies, Inc.
5 Jul 2022
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated
$13.71K 3,905 at 3.51
0.7%
TSHA Taysha Gene Therapies, Inc.
1 Jul 2022
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated
$84.45K 23,923 at 3.53
4.2%
TSHA Taysha Gene Therapies, Inc.
30 Jun 2022
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated
$51.68K 13,892 at 3.72
2.4%
TSHA Taysha Gene Therapies, Inc.
29 Jun 2022
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated
$46.95K 12,324 at 3.81
2.1%
TSHA Taysha Gene Therapies, Inc.
3 Feb 2022
Manning Paul B Director
Bought
$392.00K 50,000 at 7.84
54.2%
+54% of stake
TSHA Taysha Gene Therapies, Inc.
3 Feb 2022
Manning Paul B Director · indirect
Bought
$208.56K 26,602 at 7.84
1.3%
TSHA Taysha Gene Therapies, Inc.
2 Feb 2022
Manning Paul B Director · indirect
Bought 2×
$520.59K 67,000 at 7.77
3.4%
Largest buy in 3 yrs
TSHA Taysha Gene Therapies, Inc.
2 Feb 2022
Manning Paul B Director
Bought
$450.66K 58,000 at 7.77
170%
Largest buy in 3 yrs
TSHA Taysha Gene Therapies, Inc.
2 Feb 2022
Nagendran Sukumar Director
Bought
$80.10K 10,000 at 8.01
52.0%
First buy on file
TSHA Taysha Gene Therapies, Inc.
2 Feb 2022
Donenberg Phillip B. Director
Bought
$23.34K 3,000 at 7.78
opened
First buy on file
TSHA Taysha Gene Therapies, Inc.
24 Nov 2021
Manning Paul B Director
Bought
$29.04K 2,202 at 13.19
6.9%
TSHA Taysha Gene Therapies, Inc.
23 Nov 2021
Session R.A. II President and CEO
Bought 2×
$529.10K 42,518 at 12.44
0.5%
First buy on file
TSHA Taysha Gene Therapies, Inc.
23 Nov 2021
Manning Paul B Director
Bought
$250.80K 20,000 at 12.54
167%
+167% of stake
TSHA Taysha Gene Therapies, Inc.
20 Aug 2021
Alam Kamran Chief Financial Officer
Sold, plan not stated 2×
$198.65K 11,840 at 16.78
3.8%
TSHA Taysha Gene Therapies, Inc.
19 Aug 2021
Alam Kamran Chief Financial Officer
Sold, plan not stated 2×
$164.17K 9,967 at 16.47
3.1%
TSHA Taysha Gene Therapies, Inc.
18 Aug 2021
Alam Kamran Chief Financial Officer
Sold, plan not stated
$194.20K 11,193 at 17.35
3.4%
TSHA Taysha Gene Therapies, Inc.
1 Jul 2021
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated
$416.19K 19,706 at 21.12
3.2%
TSHA Taysha Gene Therapies, Inc.
30 Jun 2021
PRASAD SUYASH CMO and Head of R&D
Sold, plan not stated 3×
$437.49K 20,076 at 21.79
3.2%
Showing 1–50 of 53. Page 1 of 2 Older →